Tag: Health Care

Displaying 581 - 600 of 795 results.

The second session of the Federal Trade Commission/Department of Justice joint hearings on health care and competition law and policy will begin on Wednesday, March 26 at 9:15 a.m. EST. The hearings will feature representatives of the FTC, the DOJ, the Department of Health & Human Services,...
The Federal Trade Commission (FTC) and the Department of Justice (DOJ) today released a detailed schedule for the sessions of their joint hearings on health care and competition law and policy to be held March 26-28, 2003. These hearings will be held at the FTC Conference Center at 601 New Jersey...
The Commission has received a petition from Solvay S.A.
Bristol-Myers Squibb Company (BMS) settled charges that it engaged in illegal business practices to delay the entry of three low price generic pharmaceuticals that would be in direct competition with three of its branded drugs. The complaint alleged that BMS purposely made wrongful...
The Federal Trade Commission today announced that Bristol-Myers Squibb Company (Bristol) - one of the world's largest drug makers - has settled charges that it engaged in a series of anticompetitive acts over the past decade to obstruct the entry of low-price generic competition for three of...
The Federal Trade Commission and Department of Justice today released a detailed agenda for the March/April session of their joint hearings on health care and competition law and policy along with an outline of the entirety of the hearings. The websites for the hearings are located at http://www....
Quest Diagnostics settled FTC charges that its proposed acquisition of Unilab Corporation would substantially increase concentration in the clinical laboratory testing services market by agreeing to divest clinical laboratory testing assets in Northern California to Laboratory...
In response to a request by a Dayton, Ohio, physicians' group, the Federal Trade Commission staff today issued an advisory opinion concerning the proposed formation and operation of a "healthcare advocacy group" of practicing physicians in the Dayton area. According to the letter requesting the...
On January 29, 2003 the Commission filed an amicus brief in the U.S. District Court for the Eastern District of Pennsylvania regarding the pending patent litigation between SmithKline Beecham (now known as GlaxoSmithKline or GSK) and Apotex Corporation, Apotex, Inc. and Torpharm Inc. (Apotex)...
Memorandum of the Federal Trade Commission, as amicus curiae, addressing the propriety of de-listing a patent from FDA's "Orange Book," as a remedy for patent invalidity. The brief explains that improperly-maintained Orange Book listings may serve as a barrier to competition, and...
The Federal Trade Commission and the Antitrust Division of the Department of Justice today announced that their joint hearings on "Health Care and Competition Law and Policy" will begin with three days of hearings on February 26-28, 2003. The hearings on February 26, 2003 will provide an...
Baxter settled Commission concerns stemming from its $316 million proposed acquisition of Wyeth Corporation's generic injectable drug business and agreed to divest several pharmaceutical products. The Commission charged that the acquisition would reduce competition in the manufacture...
Consent Order Will Preserve Competition in Markets for Certain General Anesthetics, Neuromuscular Blocking Agents, Antiemetics, and New Injectable Iron Replacement Therapies
The Federal Trade Commission today released the materials relating to the workshop on Health Care Competition Law and Policy, held on September 9-10, 2002. The workshop focused on the implications of competition law and policy for health care financing and delivery and considered the impact of...
Chairman Timothy J. Muris in a speech today announced that the Federal Trade Commission will hold hearings on health care and competition law and policy commencing in February 2003 and continuing throughout the year. The hearings will be hosted jointly by the FTC and the Antitrust Division of the...
Today, the Food and Drug Administration (FDA) proposed to clear away unnecessary roadblocks to the approval of generic drug products. I am encouraged by the FDA's important action to address the competitive problems existing in the approval process for generic drug products.
According to the staff of the Federal Trade Commission, a bill pending before the Ohio legislature that seeks to authorize competing physicians to engage in collective bargaining with health plans over fees and other contract terms likely would increase health care costs and reduce access to care...
Following a public comment period, the Commission has approved the issuance of final consent orders and responses to the commenters of record in the matters concerning Philips Electronics and Okie Corporation. The Commission vote to approve the final consent orders was 5-0. (FTC File Nos. 022-3095...
Following a public comment period, the Commission has approved the issuance of a modified final consent order in the matter concerning Biovail Corporation (Biovail) and its branded drug Tiazac. Through the modification to the proposed order, Biovail's time to divest the relevant assets has been...

Pages